Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$1.3B
75M shares
52-week range
$10.95 – $23.75
51% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.27%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $66.6M | $85.5M | $108.1M | $137.9M | $181.0M | $216.7M | $207.5M | $255.9M |
| Cost of revenue | $23.7M | $36.5M | $44.6M | $72.3M | $79.9M | $76.0M | $75.5M | $113.3M |
| Gross profit | $42.9M | $49.1M | $63.5M | $65.6M | $101.0M | $140.7M | $132.1M | $142.6M |
| Gross margin | 64.4% | 57.4% | 58.7% | 47.6% | 55.8% | 64.9% | 63.6% | 55.7% |
| R&D | $34.5M | $39.4M | $64.7M | $90.9M | $126.4M | $181.8M | $201.8M | $173.1M |
| Operating income | −$28.0M | −$38.7M | −$60.9M | −$111.4M | −$146.8M | −$177.4M | −$209.3M | −$166.9M |
| EBITDA | −$25.1M | −$35.1M | −$57.3M | −$98.0M | −$144.8M | $48.5M | −$179.6M | −$96.3M |
| Net income | −$28.4M | −$24.6M | −$24.5M | −$100.4M | −$149.2M | $40.7M | −$187.1M | −$103.3M |
| Net margin | -42.7% | -28.7% | -22.6% | -72.8% | -82.4% | 18.8% | -90.2% | -40.4% |
| EPS (diluted) | -0.59 | -0.41 | -0.44 | -1.43 | -2.10 | 0.54 | -2.57 | -1.41 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $235M | $-2.03 | $-2.88–$-1.12 | 4 |
| 2027 | $265M | $-1.25 | $-2.65–$0.53 | 4 |
| 2028 | $323M | $-0.07 | $-0.65–$0.88 | 3 |
| 2029 | $372M | $-0.01 | $-0.01–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
www.schrodinger.comNo one on the platform currently holds SDGR.
| Institution | Shares | Reported |
|---|---|---|
| Bridgewater Associatesas of 2024-06-30 | 87,113 | $1.7M |
No one on the platform has traded SDGR yet.
| $1.9B |
| — |
| OMCLOmnicell, Inc. | $40.94 | +2.01% | $1.9B | — |
| OMDAOmada Health | $21.62 | +3.49% | $1.3B | — |
Source: Financial Modeling Prep · peers by sector/industry
$SDGR What's with the Deutsch? You guys make some good points, but for how long do I need to keep using Google Translate?
View on StockTwits ↗$SDGR Weber Du hast es auch erkannt ,welches Potential hier vorhanden ist ,. Wir stehen ganz am Anfang eines langen Trends und SDGR wird noch 3 Stellige Kurse bekommen.
View on StockTwits ↗$SDGR Die Pharmaindustrie steht vor dem größten Patentablauf-Problem seit Jahrzehnten, das sie Hunderte von Milliarden an Umsatz kosten wird; zudem strebt die FDA verkürzte Abläufe bei klinischen Studien an, was eine enorme Nachfrage nach mittels KI entwickelten Wirkstoffen auslösen dürfte.
View on StockTwits ↗$CDT If we assume all of the following are true: • The $638.3 million Sarborg valuation is accurate • CDT's 20% stake is therefore worth about $127.5 million • The stake is fully realizable Then the implied CDT share price depends on the true share count. Here is a range of stock prices based on the the non-diluted or diluted shares: OS 4.72 million ~$27.00 Share price OS 10 million ~$12.75 Share price OS 25 million ~$5.10 Share price OS 50 million ~$2.55 Share price OS 100 million ~$1.28 Share Price The delayed 10-Q matters, investors need clarity Even if the $638.3 million valuation is accepted as fact, the market may still apply discounts because: • the stake is in a private company • it has not yet been monetized So theoretical value and trading value are not necessarily the same. The table above shows the theoretical per-share value attributable to the Sarborg stake under different share-count assumptions $QQQ $RXRX $SDGR $TEM
View on StockTwits ↗$SDGR aisen draiser hawscthunta heil. heinzburgacht 14 volkswagen nischte unsbraisher piswaiser ist!!!
View on StockTwits ↗$SDGR pamp ittt may see some healthy consolidation prior to next leg up
View on StockTwits ↗$SDGR 16 haben wir durchschritten gestern beim 3 Anlauf ,jetzt geht die Fahrt langsam los Richtung 24 .,zur 1.Etappe . Sehe langfristig richtig tollen Kursen mit locker 3 Stelligen werten . Siehe Intel Zeit zum Einsteigen ist da.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Trading at 5.4× sales vs its 10.6× historical median P/S.
Fair value ≈ $33.46 · price $17.19 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.